Hormonal Contraceptives and Affective Disorders: An Updated Review
Hormonal contraceptives (HCs), approved by the FDA in 1960, have transformed women’s reproductive autonomy and freedom. These methods not only prevent unwanted pregnancies but also contribute to social mobility by enabling women to delay childbearing, pursue education, and secure careers. Modern women have achieved unprecedented levels of educational and professional success, surpassing men in graduation rates and career advancement.
Hormonal Contraceptives: How They Work
Contraceptives fall into two main categories: barrier methods (like condoms) and hormonal methods. Hormonal contraceptives use synthetic hormones—primarily progestins and sometimes estradiol—to prevent pregnancy by inhibiting ovulation, fertilization, or implantation. These hormones are delivered through various methods including daily pills, implants, intrauterine devices (IUDs), injections, and patches.
|
Figure 1 Hormonal contraceptive types. Hormonal contraceptives can be classified based on their progestin, binding affinities, and mode of administration. |
Contrary to some misconceptions, hormones from implantable or IUD methods are not localized; instead, they circulate throughout the bloodstream, interacting with receptors across the body and brain. Progestins in contraceptives do not mimic natural progesterone, displaying unique affinities for various hormone receptors. Hormonal fluctuations influence numerous psychological processes and behaviors, impacting mood, eating habits, sexual desire, stress, and reward.
Affective Disorders: Understanding the Burden
Affective disorders encompass conditions like major depressive disorder (MDD), bipolar depression, seasonal affective disorder (SAD), and premenstrual dysphoric disorder (PMDD). MDD, characterized by persistent sadness, negative thoughts, and functional impairments, affects approximately 25% of women during their lifetime, compared to 17% of men. Depression rates, particularly among adolescents, have surged in recent years, underscoring the complexity of risk factors.
Women’s higher risk of depression post-puberty and menopause highlights hormones as potential contributors. Existing treatments, such as selective serotonin reuptake inhibitors (SSRIs) and cognitive behavior therapy (CBT), have limitations, with only 30-35% of adults achieving remission. This underscores the need for better understanding and more effective treatment approaches.
Social Signal Transduction Theory of Depression
The Social Signal Transduction Theory of Depression proposes that major life stressors trigger depression through inflammatory pathways, especially social threats. Women are more likely to experience such stressors, particularly during critical periods like adolescence. Hormones, particularly estradiol, play a role by shaping threat perception, cortisol response, inflammation levels, and gene expression.
This theory suggests that hormonal contraceptives could influence depression risk by altering hormone levels, potentially leading to increased threat sensitivity, blunted stress responses, heightened inflammation, and altered gene expression.
Methodological Challenges
Heterogeneity in Contraceptive Methods
Contraceptive methods vary in compounds (progestin-only vs combined), administration (pills, IUDs, shots), dosages, and progestins (e.g., levonorgestrel, drospirenone). Different progestins interact with various hormone receptors, leading to diverse biological effects. For example, progestin androgenicity has been linked to varying responses to contraceptive methods.
Heterogeneity in Contraceptive Users
Differences in women’s biology and contraceptive use patterns complicate understanding their effects on mood and depression. Users may have diverse psychological profiles, life experiences, and health histories, influencing their responses.
Previous Research Findings
Studies on HC use and affective disorders have yielded mixed results. Some found no effect, others reported protective or worsening impacts. Many questions remain regarding specific types, dosages, and combinations of contraceptives.
No Effects: Neutral Impact
Several studies conclude that HC use has no significant impact on depression. For example, a meta-analysis by Worly and Gur (2018) on progestin-only contraceptives showed no depression effects, but the study considered adolescent users separately. McKetta and Keyes (2019) found that adolescent OC use was associated with depression, but this could be influenced by other factors like sexual behavior and stress.
These findings suggest that covariates like socio-economic status (SES) and age at first intercourse play critical roles in understanding HC impacts.
Protective Effects: HC Benefits
Positive effects of HC use have been documented in some studies. For instance, a large sample study by Cheslack-Postava and colleagues (2015) found reduced rates of depression among OC users compared to non-users. A specific subgroup, users of monophasic OCs, exhibited lower levels of depressive symptoms, possibly due to their steadier hormonal levels.
HCs containing specific progestins like drospirenone and estradiol have been shown to benefit women with premenstrual dysphoric disorder (PMDD), often outperforming SSRI treatments.
Harmful Effects: Worsening Depression
Population-based studies have reported increased depression and antidepressant use in users of certain HC methods. Skovlund et al. (2016) found that non-oral and progestin-only contraceptives were particularly linked to higher depression risks, especially in adolescents. Johansson et al. (2023) replicated these findings, using sibling analysis to support a causal link between HC use and depression in some women.
It Depends on the User and Method
HC impacts on depression vary based on user characteristics and contraceptive type. Roberts and Hansen (2017) reported that different HC types (implants, rings, norethindrone-only pills, IUDs) showed diverse effects on postpartum depression risk. Similarly, women with ADHD were more prone to increased depression risk with OC use compared to regular users.
This highlights the importance of personalized medicine approaches to contraceptive prescribing.
HC Use and Mid-Cycle Positive Affect
HCs that suppress cyclical estrogen peaks may reduce mid-cycle positive moods, contributing to depression risk. Studies suggest that hormone-suppressing methods like OCs have larger depressive effects than IUDs with the same progestin.
HC and Stress Reactivity
HCs alter stress responses by affecting cortisol reactivity and inflammatory pathways. Some research indicates that OC users show reduced cortisol responses to stress, which could be linked to higher depression risk.
Implications and Future Directions
Research on Females and Women’s Health
Investigations into female-specific mechanisms of depression and HC side effects are insufficient. Future research should prioritize understanding individual differences in hormonal responses to HC use. Mechanistic studies could illuminate both HC impacts on depression and broader female depression pathologies.
Political and Social Considerations
The political climate surrounding contraception complicates funding and research. Both pro- and anti-reproductive rights advocates often exaggerate HC risks or benefits, stifling nuanced discussion. Biased funding can skew research findings, underscoring the need for neutral, evidence-based research.
Mindful Prescribing
Healthcare providers should conduct thorough risk assessments before prescribing HC. Factors like psychiatric history, medical conditions, family history, and past reproductive experiences can predict HC-related side effects. Decision aid tools can enhance patient involvement and satisfaction, improving contraceptive adherence and efficacy.
 |
Conclusion
Hormonal contraceptives play a pivotal role in women’s reproductive autonomy and health. However, their effects on mood and depression remain complex and multifaceted. Understanding individual differences and mechanism-specific impacts is crucial for optimizing contraceptive use and reducing adverse effects. By fostering evidence-based approaches, we can better inform healthcare providers and empower women to make informed reproductive choices.
Next Steps
We invite you to share your thoughts and experiences in the comments below. By engaging in these discussions, we can contribute to a more comprehensive understanding of hormonal contraceptives and their impacts on women’s health.
Subscribe to our newsletter to stay updated with the latest insights and research on women’s health topics.
Share this article on your social media to help spread awareness and foster informed dialogue.
